CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 298 enrolled
Drug / intervention
Sulthiamedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05236842
NCT05236842Phase 2Completed
CompareCT.gov

Efficacy, Safety and Tolerability of Three Doses of Sulthiame in Patients With Obstructive Sleep Apnea.

Desitin Arzneimittel GmbH·interventional·Posted Feb 11, 2022·Updated Nov 29, 2023

In Brief

A Phase 2 clinical trial evaluating Sulthiame for Obstructive Sleep Apnea. Completed, enrolled 298 participants across 1 site.

Detailed Summary

multi-center, randomized, double-blind, placebo-controlled, dose-finding, 4-arm, parallel assignment study to evaluate the efficacy of three different doses of sulthiame (STM) compared to placebo on sleep apnea activity in adult patients with obstructive sleep apnea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedFeb 11, 2022
Enrollment StartNov 23, 2021
Primary CompletionAug 15, 2023
Study CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.4 years ago

Interventions

Sulthiamedrug

oral